The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States MA Gagnon, J Lexchin Plos medicine 5 (1), e1, 2008 | 714 | 2008 |
Corruption of pharmaceutical markets: addressing the misalignment of financial incentives and public health MA Gagnon Journal of Law, Medicine & Ethics 41 (3), 571-580, 2013 | 110 | 2013 |
The economic case for universal pharmacare: costs and benefits of publicly funded drug coverage for all Canadians MA Gagnon, G Hébert Canadian Centre for Policy Alternatives= Centre canadien de politiques …, 2010 | 70 | 2010 |
The nature of capital in the knowledge-based economy: The case of the global pharmaceutical industry MA Gagnon York University, 2009 | 57 | 2009 |
Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts D Gleeson, J Lexchin, R Labonté, B Townsend, MA Gagnon, J Kohler, ... Globalization and Health 15, 1-17, 2019 | 52 | 2019 |
Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016 MA Gagnon, KD Volesky Globalization and health 13, 1-7, 2017 | 44 | 2017 |
CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs J Lexchin, MA Gagnon Globalization and Health 10, 1-6, 2014 | 42 | 2014 |
Capital, power and knowledge according to Thorstein Veblen: Reinterpreting the knowledge-based economy MA Gagnon Journal of Economic Issues 41 (2), 593-600, 2007 | 42 | 2007 |
A roadmap to a rational pharmacare policy in Canada MA Gagnon Canadian Federation of Nurses Unions, 2014 | 40 | 2014 |
Mirror, mirror on the wall: Medicare Part D pays needlessly high brand-name drug prices compared with other OECD countries and with US government programs MA Gagnon, S Wolfe Carleton University, 2015 | 29 | 2015 |
New drug pricing: does it make any sense? MA Gagnon Prescrire international 24 (162), 192-195, 2015 | 29 | 2015 |
Combating corruption in the pharmaceutical arena J Lexchin, JC Kohler, MA Gagnon, J Crombie, P Thacker, A Shnier Indian J Med Ethics [Internet] 3 (3), 234-9, 2018 | 24 | 2018 |
Evaluating the effects of Quebec’s private–public drug insurance system SG Morgan, MA Gagnon, M Charbonneau, A Vadeboncoeur CMAJ 189 (40), E1259-E1263, 2017 | 22 | 2017 |
A better prescription: advice for a national strategy on pharmaceutical policy in Canada SG Morgan, MA Gagnon, B Mintzes, J Lexchin Healthcare policy 12 (1), 18, 2016 | 22 | 2016 |
Drug shortages: searching for a cure MA Gagnon Healthcare Policy 7 (4), 10, 2012 | 21 | 2012 |
Recherche clinique sous influence: penser les alternatives MA Gagnon Rev Prescrire 32 (342), 311-314, 2012 | 20* | 2012 |
Les réseaux de l’internationalisme statistique (1885-1914) MA Gagnon L’ère du chiffre. Systèmes statistiques et traditions nationales, Québec …, 2000 | 20 | 2000 |
Reforming private drug coverage in Canada: inefficient drug benefit design and the barriers to change in unionized settings S O’Brady, MA Gagnon, A Cassels Health Policy 119 (2), 224-231, 2015 | 16 | 2015 |
Surviving niche busters: main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs M Charbonneau, MA Gagnon Health Policy 122 (12), 1295-1301, 2018 | 13 | 2018 |
Shaping the social determinants of value through economic ghostmanagement: An institutionalist approach to capital accumulation MA Gagnon Marx, Veblen, and the Foundations of Heterodox Economics, 250-273, 2015 | 11 | 2015 |